KR102533875B1 - 항-cd19 항체 제제 - Google Patents

항-cd19 항체 제제 Download PDF

Info

Publication number
KR102533875B1
KR102533875B1 KR1020197002043A KR20197002043A KR102533875B1 KR 102533875 B1 KR102533875 B1 KR 102533875B1 KR 1020197002043 A KR1020197002043 A KR 1020197002043A KR 20197002043 A KR20197002043 A KR 20197002043A KR 102533875 B1 KR102533875 B1 KR 102533875B1
Authority
KR
South Korea
Prior art keywords
concentration
liquid formulation
antibody
formulation
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197002043A
Other languages
English (en)
Korean (ko)
Other versions
KR20190021373A (ko
Inventor
패트릭 가리델
안드레아스 란게르
마틴 헤슬링
다니엘 바인퍼트너
보도 브록스
Original Assignee
모르포시스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포시스 아게 filed Critical 모르포시스 아게
Priority to KR1020237016157A priority Critical patent/KR20230074823A/ko
Publication of KR20190021373A publication Critical patent/KR20190021373A/ko
Application granted granted Critical
Publication of KR102533875B1 publication Critical patent/KR102533875B1/ko
Assigned to 인사이트 코포레이션 reassignment 인사이트 코포레이션 권리의 전부이전등록 Assignors: 모르포시스 아게
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020197002043A 2016-06-27 2017-06-27 항-cd19 항체 제제 Active KR102533875B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237016157A KR20230074823A (ko) 2016-06-27 2017-06-27 항-cd19 항체 제제

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16176322 2016-06-27
EP16176322.2 2016-06-27
PCT/EP2017/065819 WO2018002031A1 (en) 2016-06-27 2017-06-27 Anti-cd19 antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237016157A Division KR20230074823A (ko) 2016-06-27 2017-06-27 항-cd19 항체 제제

Publications (2)

Publication Number Publication Date
KR20190021373A KR20190021373A (ko) 2019-03-05
KR102533875B1 true KR102533875B1 (ko) 2023-05-18

Family

ID=56368805

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197002043A Active KR102533875B1 (ko) 2016-06-27 2017-06-27 항-cd19 항체 제제
KR1020237016157A Ceased KR20230074823A (ko) 2016-06-27 2017-06-27 항-cd19 항체 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237016157A Ceased KR20230074823A (ko) 2016-06-27 2017-06-27 항-cd19 항체 제제

Country Status (26)

Country Link
US (2) US11352423B2 (https=)
EP (2) EP3909985A1 (https=)
JP (3) JP2019524671A (https=)
KR (2) KR102533875B1 (https=)
CN (2) CN115998859A (https=)
AU (2) AU2017289085B2 (https=)
CA (1) CA3029137A1 (https=)
CY (1) CY1124521T1 (https=)
DK (1) DK3475303T3 (https=)
ES (1) ES2874640T3 (https=)
HR (1) HRP20210945T1 (https=)
HU (1) HUE054296T2 (https=)
IL (1) IL263764B2 (https=)
LT (1) LT3475303T (https=)
MA (1) MA45450B1 (https=)
MD (1) MD3475303T2 (https=)
MX (1) MX2018016362A (https=)
PL (1) PL3475303T3 (https=)
PT (1) PT3475303T (https=)
RS (1) RS62035B1 (https=)
RU (1) RU2748024C2 (https=)
SG (2) SG11201810429UA (https=)
SI (1) SI3475303T1 (https=)
SM (1) SMT202100317T1 (https=)
WO (1) WO2018002031A1 (https=)
ZA (1) ZA201900483B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767063C2 (ru) 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование
US12358983B2 (en) 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
CN115151565A (zh) 2019-10-31 2022-10-04 莫佛塞斯公司 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法
WO2021259902A1 (en) 2020-06-22 2021-12-30 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
US20260070986A1 (en) 2021-11-03 2026-03-12 Affimed Gmbh Bispecific cd16a binders
AU2023264582A1 (en) * 2022-05-03 2024-11-21 Incyte Corporation Methods for treating lymphoma
KR20250052388A (ko) 2022-08-17 2025-04-18 인사이트 코포레이션 항-cd19 항체 및 ezh2 조절제를 포함하는 요법
EP4673177A1 (en) * 2023-03-02 2026-01-07 Novetide Ltd. Process for preparation of glp-1 peptides having controlled particle size
CN120754244B (zh) * 2025-09-10 2025-12-12 江苏豪森药业集团有限公司 一种含抗cd19抗体的药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015001504A2 (en) * 2013-07-04 2015-01-08 Neotope Biosciences Limited Antibody formulations and methods
WO2015157286A1 (en) * 2014-04-07 2015-10-15 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
RU2495882C2 (ru) 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
MX369671B (es) 2013-03-13 2019-11-15 Genentech Inc Formulaciones con oxidacion reducida.
CN110538322A (zh) 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 抗体配制剂
MY175472A (en) 2013-09-27 2020-06-29 Genentech Inc Anti-pdl1 antibody formulations
SI3071237T1 (sl) * 2013-11-21 2024-11-29 Genmab A/S Liofilizirana formulacija konjugata protitelo-zdravilo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015001504A2 (en) * 2013-07-04 2015-01-08 Neotope Biosciences Limited Antibody formulations and methods
WO2015157286A1 (en) * 2014-04-07 2015-10-15 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates

Also Published As

Publication number Publication date
CN109415440A (zh) 2019-03-01
ES2874640T3 (es) 2021-11-05
KR20190021373A (ko) 2019-03-05
JP2019524671A (ja) 2019-09-05
CN109415440B (zh) 2022-12-06
US20190322742A1 (en) 2019-10-24
IL263764B2 (en) 2024-09-01
JP2022119854A (ja) 2022-08-17
HRP20210945T1 (hr) 2021-09-17
LT3475303T (lt) 2021-06-25
CA3029137A1 (en) 2018-01-04
IL263764B1 (en) 2024-05-01
US11352423B2 (en) 2022-06-07
EP3909985A1 (en) 2021-11-17
MA45450B1 (fr) 2021-04-30
RU2748024C2 (ru) 2021-05-19
MX2018016362A (es) 2019-04-22
JP2024109816A (ja) 2024-08-14
JP7603201B2 (ja) 2024-12-20
EP3475303A1 (en) 2019-05-01
EP3475303B1 (en) 2021-04-14
PT3475303T (pt) 2021-06-25
HUE054296T2 (hu) 2021-08-30
CN115998859A (zh) 2023-04-25
MD3475303T2 (ro) 2021-09-30
SMT202100317T1 (it) 2021-07-12
JP7824990B2 (ja) 2026-03-05
DK3475303T3 (da) 2021-05-31
ZA201900483B (en) 2021-06-30
RU2019100221A (ru) 2020-07-28
SI3475303T1 (sl) 2021-12-31
AU2024205042A1 (en) 2024-08-15
WO2018002031A1 (en) 2018-01-04
AU2017289085B2 (en) 2024-07-18
NZ748681A (en) 2025-06-27
KR20230074823A (ko) 2023-05-31
PL3475303T3 (pl) 2021-12-06
US20220213190A1 (en) 2022-07-07
CY1124521T1 (el) 2022-07-22
SG11201810429UA (en) 2018-12-28
SG10201912369QA (en) 2020-02-27
RU2019100221A3 (https=) 2020-11-30
IL263764A (en) 2019-01-31
RS62035B1 (sr) 2021-07-30
AU2017289085A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
JP7824990B2 (ja) 抗ｃｄ１９抗体製剤
CN110732023A (zh) 一种her2抗体药物组合物及其用途
CA3064470A1 (en) Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof
CA3105360A1 (en) Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer
CA3096844A1 (en) Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects
CN112839961B (zh) 一种cd40抗体药物组合物及其用途
HK40064043A (en) Anti-cd19 antibody formulations
RU2848327C1 (ru) Составы на основе антитела к CD19
HK40004579B (en) Anti-cd19 antibody formulations
HK40004579A (en) Anti-cd19 antibody formulations
HK40004117B (zh) 抗-cd19抗体制剂
NZ789731A (en) Anti-CD19 antibody formulations
HK40004117A (en) Anti-cd19 antibody formulations
TW202417512A (zh) 含有抗tigit抗體的配製物及其使用方法
CA3250813A1 (en) PHARMACEUTICAL FORMULATIONS OF AN ANTI-ILT4 ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT OF IT AND METHODS OF USE

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4